Recent Updates
Recently added Catalysts
KZIA

Appendix3Y Change of Director s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and document

Key Takeaway: Director s Interest Notice Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be made public. Introduced 30/09/01 Amended 01/01/11 INa

Full Press Release Details

Director s Interest Notice
Change of Director s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property
and may be made public.
Introduced 30/09/01 Amended 01/01/11
IName of entity Kazia Therapeutics Limited ( Kazia )
rsN 37 063 259 754
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Mr lain Ross
Date of last notice 21 December 2021
Part 1 - Change of director s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of notifiable interest of a
director should be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change 6 September 2022
No. of securities held prior to change 1,075,001 ordinary shares 400,000 unlisted options
Class Ordinary shares
Number acquired 175,000
Number disposed N/A
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Change of Director s Interest Notice
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation 175,000 ordinary shares at $0.2207 per share
No. of securities held after change 1,250,001 ordinary shares 400,000 unlisted options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Purchased on market
Part 2 - Change of director s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of notifiable interest of a director should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
See chapter 19 for defined terms.
Change of Director s Interest Notice
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided?
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Change of Director s Interest Notice
Change of Director s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become
ASX s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
IName of entity Kazia Therapeutics Limited ( Kazia )
rsN 37 063 259 754
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Steven Coffey
Date of last notice 21 December 2021
Part 1 - Change of director s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of notifiable interest of a
director should be disclosed in this part.
Direct or indirect interest Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Fortune 501 Pty Limited (SR Coffey Superfund) Steven Coffey Coffey Family Investments Pty Limited
Date of change 6 & 7 September 2022
No. of securities held prior to change 426,250 ordinary shares (indirect) 8,015 ordinary shares (direct) 400,000 unlisted options (direct) 50,000 ordinary shares
Class Ordinary shares
Number acquired 50,000 ordinary shares (indirect)
Number disposed
See chapter 19 for defined terms.
01/01/20n Appendix 3Y Page 1
Change of Director s Interest Notice
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation 73,372 ordinary shares at $0.2097 per share 26,628 ordinary shares at $0.235 per share
No. of securities held after change 426,250 ordinary shares (indirect) 8,015 ordinary shares (direct) 400,000 unlisted options (direct) 100,000 ordinary shares (indirect)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Purchased on market
Part 2 - Change of director s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of notifiable interest of a director should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
See chapter 19 for defined terms.
Change of Director s Interest Notice
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided?
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Change of Director s Interest Notice
Change of Director s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become
ASX s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
IName of entity Kazia Therapeutics Limited ( Kazia )
rsN 37 063 259 754
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Dr James Garner
Date of last notice 21 December 2021
Part 1 - Change of director s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of notifiable interest of a
director should be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change 6 & 7 September 2022
No. of securities held prior to change 500,000 ordinary shares 4,500,000 unlisted options
Class Ordinary shares
Number acquired 100,000 ordinary shares
Number disposed N/A
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Change of Director s Interest Notice
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation 50,000 ordinary shares at an average price of $0.2250 50,000 ordinary shares at an average price of $0.2377
No. of securities held after change 600,000 ordinary shares 4,500,000 unlisted options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Purchased on market
Part 2 - Change of director s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of notifiable interest of a director should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
See chapter 19 for defined terms.
Change of Director s Interest Notice
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided?
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Change of Director s Interest Notice
Change of Director s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become
ASX s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
IName of entity Kazia Therapeutics Limited ( Kazia )
rsN 37 063 259 754
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Mr Bryce Carmine
Date of last notice 21 December 2021
Part 1 - Change of director s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of notifiable interest of a
director should be disclosed in this part.
Last updated: Sep 8, 2022